Company Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 20, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 479 |
| CEO | Sushil Patel |
Contact Details
Address: 500 Unicorn Park Drive, Suite 303 Woburn, Massachusetts 01801 United States | |
| Phone | (781) 222-9600 |
| Website | replimune.com |
Stock Details
| Ticker Symbol | REPL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001737953 |
| CUSIP Number | 76029N106 |
| ISIN Number | US76029N1063 |
| Employer ID | 82-2082553 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sushil Patel Ph.D. | Chief Executive Officer and Director |
| Emily Luisa Hill | Chief Financial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Philip Astley-Sparke F.S.A. | Executive Chairman |
| Andrew Schwendenman | Chief Accounting Officer and Treasurer |
| Shawn Glidden J.D. | Senior Vice President and General Counsel |
| Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
| Christopher Sarchi | Chief Commercial Officer |
| Paul Bullock | Chief Manufacturing Officer and Framingham Site Head |
| Nina Aragam | Senior Vice President of Portfolio Strategy and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 31, 2025 | SCHEDULE 13G | Filing |
| Jul 25, 2025 | ARS | Filing |
| Jul 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 25, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 22, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| May 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |